Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

BMI1 drives metastasis of prostate cancer in Caucasian and African-American men and is a potential therapeutic target: hypothesis tested in race-specific models.

Ganaie A, Beigh FH, Astone M, Ferrari MG, Maqbool R, Umbreen S, Parray AS, Siddique HR, Hussain T, Murugan P, Morrissey C, Koochekpour S, Deng Y, Konety BR, Hoeppner LH, Saleem M.

Clin Cancer Res. 2018 Aug 7. pii: clincanres.1394.2018. doi: 10.1158/1078-0432.CCR-18-1394. [Epub ahead of print]

PMID:
30087142
2.

Correction: A comprehensive analysis of coregulator recruitment, androgen receptor function and gene expression in prostate cancer.

Liu S, Kumari S, Hu Q, Senapati D, Venkadakrishnan VB, Wang D, DePriest AD, Schlanger SE, Ben-Salem S, Valenzuela MM, Willard B, Mudambi S, Swetzig WM, Das GM, Shourideh M, Koochekpour S, Falzarano SM, Magi-Galluzzi C, Yadav N, Chen X, Lao C, Wang J, Billaud JN, Heemers HV.

Elife. 2017 Nov 22;6. pii: e33738. doi: 10.7554/eLife.33738. No abstract available.

3.

Reversion of epithelial-mesenchymal transition by a novel agent DZ-50 via IGF binding protein-3 in prostate cancer cells.

Cao Z, Koochekpour S, Strup SE, Kyprianou N.

Oncotarget. 2017 Jul 28;8(45):78507-78519. doi: 10.18632/oncotarget.19659. eCollection 2017 Oct 3.

4.

A comprehensive analysis of coregulator recruitment, androgen receptor function and gene expression in prostate cancer.

Liu S, Kumari S, Hu Q, Senapati D, Venkadakrishnan VB, Wang D, DePriest AD, Schlanger SE, Ben-Salem S, Valenzuela MM, Willard B, Mudambi S, Swetzig WM, Das GM, Shourideh M, Koochekpour S, Falzarano SM, Magi-Galluzzi C, Yadav N, Chen X, Lao C, Wang J, Billaud JN, Heemers HV.

Elife. 2017 Aug 18;6. pii: e28482. doi: 10.7554/eLife.28482. Erratum in: Elife. 2017 Nov 22;6:.

5.

Androgen receptor splice variants and prostate cancer: From bench to bedside.

Wadosky KM, Koochekpour S.

Oncotarget. 2017 Mar 14;8(11):18550-18576. doi: 10.18632/oncotarget.14537. Review.

6.

Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.

Wadosky KM, Koochekpour S.

Oncotarget. 2016 Sep 27;7(39):64447-64470. doi: 10.18632/oncotarget.10901. Review.

7.

GRM1 is An Androgen-Regulated Gene and its Expression Correlates with Prostate Cancer Progression in Pre-Clinical Models.

Shourideh M, Azabdaftari G, Attwood K, DePriest A, Wadosky KM, Gillard BM, Karasik E, Heemers H, Kyprianou N, Gelman IH, Corey E, Vessella RL, Mohler JL, Koochekpour S.

Clin Cancer Res. 2016 Jul 25. pii: clincanres.0137.2016. doi: 10.1158/1078-0432.CCR-16-0137. [Epub ahead of print] Retraction in: Clin Cancer Res. 2017 Jul 15;23 (14 ):3973.

PMID:
27458247
8.

Characterization of fibroblast-free CWR-R1ca castration-recurrent prostate cancer cell line.

Shourideh M, DePriest A, Mohler JL, Wilson EM, Koochekpour S.

Prostate. 2016 Sep;76(12):1067-77. doi: 10.1002/pros.23190. Epub 2016 Jun 8.

PMID:
27271795
9.

Mitochondrial dysfunction-mediated apoptosis resistance associates with defective heat shock protein response in African-American men with prostate cancer.

Chaudhary AK, Bhat TA, Kumar S, Kumar A, Kumar R, Underwood W, Koochekpour S, Shourideh M, Yadav N, Dhar S, Chandra D.

Br J Cancer. 2016 May 10;114(10):1090-100. doi: 10.1038/bjc.2016.88. Epub 2016 Apr 26.

10.

Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer.

Wadosky KM, Koochekpour S.

Int J Biol Sci. 2016 Feb 6;12(4):409-26. doi: 10.7150/ijbs.14090. eCollection 2016. Review.

11.
12.

Hexokinase 2-mediated Warburg effect is required for PTEN- and p53-deficiency-driven prostate cancer growth.

Wang L, Xiong H, Wu F, Zhang Y, Wang J, Zhao L, Guo X, Chang LJ, Zhang Y, You MJ, Koochekpour S, Saleem M, Huang H, Lu J, Deng Y.

Cell Rep. 2014 Sep 11;8(5):1461-74. doi: 10.1016/j.celrep.2014.07.053. Epub 2014 Aug 28.

13.

Establishment and characterization of a highly tumorigenic African American prostate cancer cell line, E006AA-hT.

Koochekpour S, Willard SS, Shourideh M, Ali S, Liu C, Azabdaftari G, Saleem M, Attwood K.

Int J Biol Sci. 2014 Jul 26;10(8):834-45. doi: 10.7150/ijbs.9406. eCollection 2014.

14.

Identification of novel GRM1 mutations and single nucleotide polymorphisms in prostate cancer cell lines and tissues.

Ali S, Shourideh M, Koochekpour S.

PLoS One. 2014 Jul 25;9(7):e103204. doi: 10.1371/journal.pone.0103204. eCollection 2014.

15.

Biological and clinical significance of androgens and androgen receptor in prostate cancer.

Koochekpour S.

Int J Biol Sci. 2014 Jun 10;10(6):652-3. doi: 10.7150/ijbs.9576. eCollection 2014. No abstract available.

16.

Androgen receptor mutations and polymorphisms in African American prostate cancer.

Koochekpour S, Buckles E, Shourideh M, Hu S, Chandra D, Zabaleta J, Attwood K.

Int J Biol Sci. 2014 Jun 5;10(6):643-51. doi: 10.7150/ijbs.8974. eCollection 2014.

17.

ROBO1, a tumor suppressor and critical molecular barrier for localized tumor cells to acquire invasive phenotype: study in African-American and Caucasian prostate cancer models.

Parray A, Siddique HR, Kuriger JK, Mishra SK, Rhim JS, Nelson HH, Aburatani H, Konety BR, Koochekpour S, Saleem M.

Int J Cancer. 2014 Dec 1;135(11):2493-506. doi: 10.1002/ijc.28919. Epub 2014 Apr 29.

18.

Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients.

Singh PK, Preus L, Hu Q, Yan L, Long MD, Morrison CD, Nesline M, Johnson CS, Koochekpour S, Kohli M, Liu S, Trump DL, Sucheston-Campbell LE, Campbell MJ.

Oncotarget. 2014 Feb 15;5(3):824-40.

19.

Cofilin drives cell-invasive and metastatic responses to TGF-β in prostate cancer.

Collazo J, Zhu B, Larkin S, Martin SK, Pu H, Horbinski C, Koochekpour S, Kyprianou N.

Cancer Res. 2014 Apr 15;74(8):2362-73. doi: 10.1158/0008-5472.CAN-13-3058. Epub 2014 Feb 7. Erratum in: Cancer Res. 2018 Sep 1;78(17):5180.

20.

Glutamate, glutamate receptors, and downstream signaling pathways.

Willard SS, Koochekpour S.

Int J Biol Sci. 2013 Sep 22;9(9):948-59. doi: 10.7150/ijbs.6426. eCollection 2013. Review.

21.

Reduced mitochondrial DNA content associates with poor prognosis of prostate cancer in African American men.

Koochekpour S, Marlowe T, Singh KK, Attwood K, Chandra D.

PLoS One. 2013 Sep 23;8(9):e74688. doi: 10.1371/journal.pone.0074688. eCollection 2013.

22.

Glutamate signaling in benign and malignant disorders: current status, future perspectives, and therapeutic implications.

Willard SS, Koochekpour S.

Int J Biol Sci. 2013 Aug 9;9(7):728-42. doi: 10.7150/ijbs.6475. eCollection 2013. Review.

23.

Androgen-responsive serum response factor target genes regulate prostate cancer cell migration.

Verone AR, Duncan K, Godoy A, Yadav N, Bakin A, Koochekpour S, Jin JP, Heemers HV.

Carcinogenesis. 2013 Aug;34(8):1737-46. doi: 10.1093/carcin/bgt126. Epub 2013 Apr 10.

24.

Polycyclic aromatic hydrocarbons-induced ROS accumulation enhances mutagenic potential of T-antigen from human polyomavirus JC.

Wilk A, Waligórski P, Lassak A, Vashistha H, Lirette D, Tate D, Zea AH, Koochekpour S, Rodriguez P, Meggs LG, Estrada JJ, Ochoa A, Reiss K.

J Cell Physiol. 2013 Nov;228(11):2127-38. doi: 10.1002/jcp.24375.

25.

Glutamate, a metabolic biomarker of aggressiveness and a potential therapeutic target for prostate cancer.

Koochekpour S.

Asian J Androl. 2013 Mar;15(2):212-3. doi: 10.1038/aja.2012.145. Epub 2013 Jan 14. No abstract available.

26.

BMI1, stem cell factor acting as novel serum-biomarker for Caucasian and African-American prostate cancer.

Siddique HR, Parray A, Zhong W, Karnes RJ, Bergstralh EJ, Koochekpour S, Rhim JS, Konety BR, Saleem M.

PLoS One. 2013;8(1):e52993. doi: 10.1371/journal.pone.0052993. Epub 2013 Jan 7. Erratum in: PLoS One. 2013;8(6). doi:10.1371/annotation/d612ee51-4c8e-4468-8373-3d4c503f0da5.

27.

Regulators of gene expression as biomarkers for prostate cancer.

Willard SS, Koochekpour S.

Am J Cancer Res. 2012;2(6):620-57. Epub 2012 Nov 20.

28.

Resveratrol depletes mitochondrial DNA and inhibition of autophagy enhances resveratrol-induced caspase activation.

Prabhu V, Srivastava P, Yadav N, Amadori M, Schneider A, Seshadri A, Pitarresi J, Scott R, Zhang H, Koochekpour S, Gogada R, Chandra D.

Mitochondrion. 2013 Sep;13(5):493-9. doi: 10.1016/j.mito.2012.10.010. Epub 2012 Oct 23.

29.

Serum glutamate levels correlate with Gleason score and glutamate blockade decreases proliferation, migration, and invasion and induces apoptosis in prostate cancer cells.

Koochekpour S, Majumdar S, Azabdaftari G, Attwood K, Scioneaux R, Subramani D, Manhardt C, Lorusso GD, Willard SS, Thompson H, Shourideh M, Rezaei K, Sartor O, Mohler JL, Vessella RL.

Clin Cancer Res. 2012 Nov 1;18(21):5888-901. doi: 10.1158/1078-0432.CCR-12-1308. Epub 2012 Oct 16.

30.

Aberrant DNA methylation and prostate cancer.

Majumdar S, Buckles E, Estrada J, Koochekpour S.

Curr Genomics. 2011 Nov;12(7):486-505. doi: 10.2174/138920211797904061.

31.

DNA methylome and the complexity of discovering prostate cancer biomarkers.

Koochekpour S.

Asian J Androl. 2011 Sep;13(5):661-2. doi: 10.1038/aja.2011.90. Epub 2011 Jul 4. No abstract available.

32.

Serum prosaposin levels are increased in patients with advanced prostate cancer.

Koochekpour S, Hu S, Vellasco-Gonzalez C, Bernardo R, Azabdaftari G, Zhu G, Zhau HE, Chung LW, Vessella RL.

Prostate. 2012 Feb;72(3):253-69. doi: 10.1002/pros.21427. Epub 2011 May 31. Erratum in: Prostate. 2014 May;74(7):804.

33.

Genetic and epigenetic changes in human prostate cancer.

Koochekpour S.

Iran Red Crescent Med J. 2011 Feb;13(2):80-98. Epub 2011 Feb 1.

34.

Androgen receptor signaling and mutations in prostate cancer.

Koochekpour S.

Asian J Androl. 2010 Sep;12(5):639-57. doi: 10.1038/aja.2010.89. Epub 2010 Aug 16. Review.

35.

Loss of androgen receptor-dependent growth suppression by prostate cancer cells can occur independently from acquiring oncogenic addiction to androgen receptor signaling.

D'Antonio JM, Vander Griend DJ, Antony L, Ndikuyeze G, Dalrymple SL, Koochekpour S, Isaacs JT.

PLoS One. 2010 Jul 8;5(7):e11475. doi: 10.1371/journal.pone.0011475.

36.

Poly(ADP-ribose) polymerase-1 is a determining factor in Crm1-mediated nuclear export and retention of p65 NF-kappa B upon TLR4 stimulation.

Zerfaoui M, Errami Y, Naura AS, Suzuki Y, Kim H, Ju J, Liu T, Hans CP, Kim JG, Abd Elmageed ZY, Koochekpour S, Catling A, Boulares AH.

J Immunol. 2010 Aug 1;185(3):1894-902. doi: 10.4049/jimmunol.1000646. Epub 2010 Jul 7.

37.
38.

Identification of a novel germline missense mutation of the androgen receptor in African American men with familial prostate cancer.

Hu SY, Liu T, Liu ZZ, Ledet E, Velasco-Gonzalez C, Mandal DM, Koochekpour S.

Asian J Androl. 2010 May;12(3):336-43. doi: 10.1038/aja.2010.5. Epub 2010 Feb 22.

39.

Prosaposin down-modulation decreases metastatic prostate cancer cell adhesion, migration, and invasion.

Hu S, Delorme N, Liu Z, Liu T, Velasco-Gonzalez C, Garai J, Pullikuth A, Koochekpour S.

Mol Cancer. 2010 Feb 4;9:30. doi: 10.1186/1476-4598-9-30.

40.

Optimal transactivation by Epstein-Barr nuclear antigen 1 requires the UR1 and ATH1 domains.

Singh G, Aras S, Zea AH, Koochekpour S, Aiyar A.

J Virol. 2009 May;83(9):4227-35. doi: 10.1128/JVI.02578-08. Epub 2009 Feb 25.

41.

Prosaposin is an AR-target gene and its neurotrophic domain upregulates AR expression and activity in prostate stromal cells.

Koochekpour S, Lee TJ, Sun Y, Hu S, Grabowski GA, Liu Z, Garay J.

J Cell Biochem. 2008 Aug 15;104(6):2272-85. doi: 10.1002/jcb.21786.

PMID:
18481277
42.

Proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor enhances androgen receptor functions through LIM-only coactivator, four-and-a-half LIM-only protein 2.

Nair SS, Guo Z, Mueller JM, Koochekpour S, Qiu Y, Tekmal RR, Schüle R, Kung HJ, Kumar R, Vadlamudi RK.

Mol Endocrinol. 2007 Mar;21(3):613-24. Epub 2006 Dec 27.

43.

Prosaposin is a novel androgen-regulated gene in prostate cancer cell line LNCaP.

Koochekpour S, Lee TJ, Wang R, Sun Y, Delorme N, Hiraiwa M, Grabowski GA, Culig Z, Minokadeh A.

J Cell Biochem. 2007 Jun 1;101(3):631-41.

PMID:
17171640
44.

Survivin is not only a death encounter but also a survival protein for invading tumor cells.

Ouhtit A, Matrougui K, Bengrine A, Koochekpour S, Zerfaoui M, Yousief Z.

Front Biosci. 2007 Jan 1;12:1260-70. Review.

PMID:
17127378
45.

Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).

Koochekpour S, Lee TJ, Wang R, Culig Z, Delorme N, Caffey S, Marrero L, Aguirre J.

Prostate. 2007 Feb 1;67(2):178-89.

PMID:
17044040
46.

Pleomorphic adenoma of the trachea in an 8-year-old boy: a case report.

Baghai-Wadji M, Sianati M, Nikpour H, Koochekpour S.

J Pediatr Surg. 2006 Aug;41(8):e23-6.

PMID:
16863832
47.

Amplification and overexpression of prosaposin in prostate cancer.

Koochekpour S, Zhuang YJ, Beroukhim R, Hsieh CL, Hofer MD, Zhau HE, Hiraiwa M, Pattan DY, Ware JL, Luftig RB, Sandhoff K, Sawyers CL, Pienta KJ, Rubin MA, Vessella RL, Sellers WR, Sartor O.

Genes Chromosomes Cancer. 2005 Dec;44(4):351-64.

PMID:
16080200
49.

Saposin C stimulates growth and invasion, activates p42/44 and SAPK/JNK signaling pathways of MAPK and upregulates uPA/uPAR expression in prostate cancer and stromal cells.

Koochekpour S, Sartor O, Hiraiwa M, Lee TJ, Rayford W, Remmel N, Sandhoff K, Minokadeh A, Patten DY.

Asian J Androl. 2005 Jun;7(2):147-58.

50.

Supplemental Content

Loading ...
Support Center